利用自然杀伤 T（NKT）细胞治疗人类骨髓瘤：进展与挑战。
Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.
机构信息
Section of Hematology, Yale University, New Haven, CT 06510, USA.
出版信息
Clin Immunol. 2011 Aug;140(2):160-6. doi: 10.1016/j.clim.2010.12.010. Epub 2011 Jan 12.
Abstract
Multiple myeloma is a hematologic malignancy characterized by growth of malignant plasma cells in the bone marrow. Tumor cells in myeloma express CD1d and are sensitive to lysis by CD1d restricted natural killer T (NKT) cells. Here we discuss recent studies to harness the properties of these cells in the context of human myeloma. In spite of large body of preclinical data, attempts to fully harness the properties of these cells in the clinic are in early stages. Early phase clinical studies document the capacity of human monocyte-derived dendritic cells to expand NKT cells in vivo in myeloma patients. These results have set the stage for ongoing studies combining NKT activation with immune-modulatory drugs. Lessons learnt from these studies may inform the optimal application of human NKT based therapies in other settings as well.
摘要
多发性骨髓瘤是一种血液系统恶性肿瘤，其特征是骨髓中恶性浆细胞的生长。骨髓瘤细胞表达 CD1d，并对 CD1d 限制的自然杀伤 T（NKT）细胞的溶解敏感。在这里，我们讨论了利用这些细胞在人类骨髓瘤中的特性的最新研究。尽管有大量的临床前数据，但在临床中充分利用这些细胞的特性的尝试仍处于早期阶段。早期的临床研究记录了人单核细胞衍生的树突状细胞在骨髓瘤患者体内体内扩增 NKT 细胞的能力。这些结果为正在进行的研究奠定了基础，即将 NKT 激活与免疫调节药物相结合。从这些研究中吸取的经验教训可能会为在其他情况下最佳应用基于人类 NKT 的治疗提供信息。
相似文献
1
Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.利用自然杀伤 T（NKT）细胞治疗人类骨髓瘤：进展与挑战。
Clin Immunol. 2011 Aug;140(2):160-6. doi: 10.1016/j.clim.2010.12.010. Epub 2011 Jan 12.
2
Harnessing CD1d-restricted T cells toward antitumor immunity in humans.利用CD1d限制性T细胞实现人类抗肿瘤免疫。
Ann N Y Acad Sci. 2009 Sep;1174:61-7. doi: 10.1111/j.1749-6632.2009.04931.x.
3
Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.使用自然杀伤细胞相关标志物定义新型 CD1d 依赖性 II 型自然杀伤 T 细胞亚群。
Scand J Immunol. 2019 Sep;90(3):e12794. doi: 10.1111/sji.12794. Epub 2019 Jun 26.
4
Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis.酸性依赖的 CD1d 限制性自然杀伤 T 细胞的激活在囊性纤维化中是完整的。
Immunology. 2010 Jun;130(2):288-95. doi: 10.1111/j.1365-2567.2009.03234.x. Epub 2010 Jan 19.
5
Application of natural killer T cells in antitumor immunotherapy.自然杀伤T细胞在抗肿瘤免疫治疗中的应用。
Crit Rev Immunol. 2007;27(6):511-25. doi: 10.1615/critrevimmunol.v27.i6.20.
6
Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.载有α-半乳糖神经酰胺的肿瘤细胞促进多发性骨髓瘤中 NKT 依赖性抗肿瘤免疫治疗。
Immunol Lett. 2013 Nov-Dec;156(1-2):132-9. doi: 10.1016/j.imlet.2013.10.002. Epub 2013 Oct 19.
7
Benzofuran sulfonates and small self-lipid antigens activate type II NKT cells via CD1d.苯并呋喃磺酸盐和小分子自身脂质抗原通过CD1d激活II型自然杀伤T细胞。
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34). doi: 10.1073/pnas.2104420118.
8
NKT and tolerance.自然杀伤T细胞与免疫耐受
Methods Mol Biol. 2011;677:193-206. doi: 10.1007/978-1-60761-869-0_14.
9
Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.新型 CD1d 结合型 NKT 细胞配体作为疫苗佐剂的临床开发。
Clin Immunol. 2011 Aug;140(2):142-51. doi: 10.1016/j.clim.2010.11.009. Epub 2010 Dec 24.
10
Human NKT cells express granulysin and exhibit antimycobacterial activity.人类自然杀伤T细胞表达颗粒溶素并表现出抗分枝杆菌活性。
J Immunol. 2003 Mar 15;170(6):3154-61. doi: 10.4049/jimmunol.170.6.3154.
引用本文的文献
1
Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms.揭开肥胖与多发性骨髓瘤之谜：来自流行病学和分子机制的见解
Curr Obes Rep. 2025 Jun 5;14(1):52. doi: 10.1007/s13679-025-00644-w.
2
Role of Immune Cells and Immunotherapy in Multiple Myeloma.免疫细胞与免疫疗法在多发性骨髓瘤中的作用
Life (Basel). 2024 Apr 1;14(4):461. doi: 10.3390/life14040461.
3
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).利用同种异体不变自然杀伤 T 细胞（iNKT）克服对程序性细胞死亡蛋白 1（PD-1）阻断的抵抗。
Oncogene. 2024 Mar;43(10):758-762. doi: 10.1038/s41388-024-02948-y. Epub 2024 Jan 29.
4
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.泊马度胺联合万珂和地塞米松治疗复发/难治性多发性骨髓瘤患者时对NK、NKT及B/T细胞亚群的免疫调节作用及其与无进展生存期改善的关联
Front Oncol. 2023 Dec 4;13:1271807. doi: 10.3389/fonc.2023.1271807. eCollection 2023.
5
Obesity as a risk factor for multiple myeloma: insight on the role of adipokines.肥胖作为多发性骨髓瘤的一个风险因素：关于脂肪因子作用的见解。
Pathol Oncol Res. 2023 Aug 10;29:1611338. doi: 10.3389/pore.2023.1611338. eCollection 2023.
6
Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment.纳米抗体衍生的双特异性嵌合抗原受体T细胞疗法增强了T细胞淋巴瘤治疗的抗肿瘤疗效。
Mol Ther Oncolytics. 2023 Jul 28;30:86-102. doi: 10.1016/j.omto.2023.07.007. eCollection 2023 Sep 21.
7
Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.鞘脂类在多发性骨髓瘤进展、耐药性中的作用及其作为治疗靶点的潜力
Front Oncol. 2022 Jun 8;12:925807. doi: 10.3389/fonc.2022.925807. eCollection 2022.
8
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.单细胞 RNA 测序揭示多发性骨髓瘤前体阶段免疫微环境受损。
Nat Cancer. 2020 May;1(5):493-506. doi: 10.1038/s43018-020-0053-3. Epub 2020 Apr 27.
9
Current Progress in CAR-T Cell Therapy for Hematological Malignancies.嵌合抗原受体T细胞（CAR-T）疗法治疗血液系统恶性肿瘤的当前进展
J Cancer. 2021 Jan 1;12(2):326-334. doi: 10.7150/jca.48976. eCollection 2021.
10
The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.人类 γδ T 细胞在抗肿瘤免疫中的作用及其在癌症免疫治疗中的潜力。
Cells. 2020 May 13;9(5):1206. doi: 10.3390/cells9051206.
本文引用的文献
1
Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.CD1d+TRAMP 前列腺肿瘤细胞通过缺陷 NKT 细胞激活是由白细胞介素-12 与 α-半乳糖神经酰胺纠正的。
PLoS One. 2010 Jun 25;5(6):e11311. doi: 10.1371/journal.pone.0011311.
2
Human leukemic cells loaded with alpha-galactosylceramide (alpha-GalCer) activate murine NKT cells in situ.载有α-半乳糖神经酰胺（α-GalCer）的人白血病细胞在体内激活小鼠 NKT 细胞。
Int J Hematol. 2010 Jul;92(1):152-60. doi: 10.1007/s12185-010-0616-7. Epub 2010 Jun 16.
3
Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.检测来那度胺治疗骨髓增生异常综合征患者中的 NKT 细胞假说。
Leukemia. 2010 Mar;24(3):592-600. doi: 10.1038/leu.2009.279. Epub 2010 Jan 14.
4
Linking inflammation to natural killer T cell activation.将炎症与自然杀伤 T 细胞激活联系起来。
PLoS Biol. 2009 Oct;7(10):e1000226. doi: 10.1371/journal.pbio.1000226. Epub 2009 Oct 27.
5
Recognition of lyso-phospholipids by human natural killer T lymphocytes.人自然杀伤 T 淋巴细胞对溶磷脂的识别。
PLoS Biol. 2009 Oct;7(10):e1000228. doi: 10.1371/journal.pbio.1000228. Epub 2009 Oct 27.
6
Harnessing CD1d-restricted T cells toward antitumor immunity in humans.利用CD1d限制性T细胞实现人类抗肿瘤免疫。
Ann N Y Acad Sci. 2009 Sep;1174:61-7. doi: 10.1111/j.1749-6632.2009.04931.x.
7
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.糖脂负载的动力学和细胞位点控制自然杀伤T细胞激活的结果。
Immunity. 2009 Jun 19;30(6):888-98. doi: 10.1016/j.immuni.2009.03.022.
8
Determination of cellular lipids bound to human CD1d molecules.与人类CD1d分子结合的细胞脂质的测定
PLoS One. 2009;4(5):e5325. doi: 10.1371/journal.pone.0005325. Epub 2009 May 5.
9
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.Vα24不变自然杀伤T细胞通过杀伤肿瘤相关巨噬细胞介导抗肿瘤活性。
J Clin Invest. 2009 Jun;119(6):1524-36. doi: 10.1172/JCI37869.
10
Natural lipid ligands associated with human CD1d targeted to different subcellular compartments.与人类CD1d相关的天然脂质配体靶向不同的亚细胞区室。
J Immunol. 2009 Apr 15;182(8):4784-91. doi: 10.4049/jimmunol.0803981.
Zotero 插件